Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05695261 · ClinicalTrials.gov registry record · Phase 2
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
A Phase 2 study of Food Allergy and Peanut Allergy, sponsored by Rima Rachid.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
- 1
- Study location
NCT05695261: Recruiting Phase 2 study of Food Allergy and Peanut Allergy, sponsored by Rima Rachid.
NCT05695261 is a Phase 2 study of Food Allergy and Peanut Allergy that is actively recruiting participants, run by Rima Rachid. The registered enrollment target is 37 participants, below the 962-participant average among 17 other Food Allergy trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05695261, a Phase 2 study of Food Allergy and Peanut Allergy, is actively recruiting participants, sponsored by Rima Rachid.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase II trial that aims at evaluating the safety and tolerability of oral encapsulated fecal microbial transplantation therapy (MTT) in peanut allergic patients. In this research the investigators would like to learn more about ways to treat peanut allergies. The primary objective for Part A is to evaluate whether MTT with antibiotic pretreatment can increase the threshold of peanut reactivity during a double-blind placebo-controlled food challenge from \<=100 mg peanut protein to 300 mg after 28 days of MTT /placebo therapy and 4 months post therapy initiation. The primary objective for Part B is to evaluate whether MTT with antibiotic pretreatment can lead to sustained unresponsiveness (SU) defined as tolerating the same dose of peanut protein administered during a food challenge at baseline and 12 weeks after OIT cessation.
Primary Outcome
PART A: Changes in threshold of peanut reactivity during DBPCFC after 28 days of MTT from \<=100 mg to 300 mg peanut protein and 4 months post therapy initiation.
Conditions Studied
Interventions
- DRUG Antibiotic
- BIOLOGICAL Microbial Transplantation Therapy
- OTHER Placebo (in place of MTT)
- OTHER Placebo (in place of antibiotics)
- OTHER Oral Immunotherapy (OIT)
Study Locations (1)
Massachusetts
- Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2023-06-08 |
| Est. Completion | 2027-03-01 |
| Phase | Phase 2 |
What NCT05695261 shows while recruiting
NCT05695261 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 962-participant average among 17 other Food Allergy trials with a reported enrollment target (96% lower).
The record links to 6 conditions, with Food Allergy appearing as the primary indexed condition, and to 5 interventions - of which Antibiotic is the first listed.
NCT05695261 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05695261 about?
NCT05695261 is a clinical study titled "Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients". This is a phase II trial that aims at evaluating the safety and tolerability of oral encapsulated fecal microbial transplantation therapy (MTT) in peanut allergic patients. In this research the investigators would like to learn more about ways to treat peanut allergies. The primary objective for Par...
What is the current status of trial NCT05695261?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2023-06-08. Estimated completion is 2027-03-01.
What conditions does trial NCT05695261 study?
This clinical trial studies the following conditions: Food Allergy, Peanut Allergy, Food Allergy Peanut, Peanut Hypersensitivity, Allergy, Peanut.
What interventions are being tested in trial NCT05695261?
The interventions under investigation include: Antibiotic (DRUG), Microbial Transplantation Therapy (BIOLOGICAL), Placebo (in place of MTT) (OTHER), Placebo (in place of antibiotics) (OTHER), Oral Immunotherapy (OIT) (OTHER).
Who is sponsoring clinical trial NCT05695261?
This trial is sponsored by Rima Rachid, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05695261 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Food Allergy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05695261's enrollment target sits among peer trials
37 12th of 17 higher than 6 of 17 other Food Allergy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Food Allergy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Omalizumab Weight-Based Dosing Efficacy Trial
RECRUITING · Phase 2
-
Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy
COMPLETED · Phase 2
-
Baked Egg or Egg Oral Immunotherapy for Children With Egg Allergy
COMPLETED · Phase 2
-
Multi Immunotherapy to Test Tolerance and Xolair
COMPLETED · Phase 2
-
Preventing Anaphylaxis With Acalabrutinib
COMPLETED · Phase 2
-
Effect of Omalizumab in the Skin of Food Allergy Patients
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI